Hydrocephalus Market Analysis | 2022-2028

“The Hydrocephalus Market was estimated at US$ 7.1 billion in 2021 and is expected to grow at a CAGR of 4.35% during 2022-2028 to reach US$ 8.56 billion in 2028.”

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Hydrocephalus is a medical condition characterized by an abnormal accumulation of cerebrospinal fluid (CSF) in the brain's ventricles, leading to increased intracranial pressure. This can result from impaired CSF circulation, absorption, or overproduction. Common symptoms include headaches, nausea, and vision problems.

Hydrocephalus can be congenital or acquired due to conditions like tumors, infections, or trauma. Treatment often involves surgical interventions, such as shunt placement, to divert excess fluid and alleviate pressure. Early diagnosis and management are crucial to prevent potential neurological complications and improve the quality of life for individuals affected by hydrocephalus.

Market Drivers

The central nervous system is shielded from infections and damage by the cerebrospinal fluid (CSF) in the brain and spinal cord. The build-up of extra CSF in brain cavities increases intracranial pressure, which in turn causes hydrocephalus. Further complications from the syndrome include macrocephaly and cognitive impairment. Compared to adults, children, and newborns are more likely to have hydrocephalus. Additionally, the disease is also prevalent in people aged 60 and above.

Cerebrospinal fluid (CSF) build-up in the brain is referred to as hydrocephalus, a condition. It is the abnormal accumulation of fluid in the deep cavities of the brain. One of the most frequent causes of brain surgery in young children is hydrocephalus. According to information provided by the Hydrocephalus Organization, 1 in 770 newborns and 1 in 100 elderly persons in America suffer from hydrocephalus, a neurological condition. This chronic illness is currently affecting more than 1 million Americans. Additionally, a brain operation related to hydrocephalus is conducted in the United States once every 15 minutes.

The incidence of brain damage cases has increased because of more accidents, self-harm, and falls. A brain injury can alter how the brain normally functions and result in long-term health problems. The main factor causing disability is traumatic brain damage. The CDC estimates that 80,000 to 90,000 Americans experience traumatic brain injury each year, leaving them incapacitated.

Additionally, severe damage, hemorrhagic stroke therapy, and acquired brain injury can all result in hydrocephalus. If the CSF flow is interrupted or the CSF pressure increases because of brain damage, hydrocephalus may result. The prevalence of hydrocephalus has increased because of more accidents.

The focus of several private and governmental organizations on raising awareness of hydrocephalus is anticipated to favor the market expansion for hydrocephalus shunts throughout the forecast period. Organizations like the "Hydrocephalus Association" are concentrating on running awareness campaigns for hydrocephalus and providing the affected individuals with the necessary programs.

Additionally, these organizations support hydrocephalus research to enhance treatment and find a cure. To speed up hydrocephalus research and treatment support, the Hydrocephalus Association launched a new national campaign called "Roadmap to a Cure" that will see the group invest $20 million by 2020.

Several investments/guidelines in the market have been directed in recent years, which would boost the overall market. Some of them are:

• Over 1 million Americans suffer from the condition, according to the Hydrocephalus Association. Additionally, one out of every 770 babies in the US are born with hydrocephalus. According to the 2019 Journal of Neurosurgery (JNS) paper "Global Hydrocephalus Epidemiology and Incidence: Systematic Review and Meta-analysis," low-income and middle-income countries, notably those in Africa and Latin America, bear the greatest burden of hydrocephalus. According to the report, Sub-Saharan Africa experiences more than 225,000 new instances of infant hydrocephalus annually, or 750 new cases for every 100,000 live births. In addition, 110 occurrences of infantile hydrocephalus were expected to occur in a European cohort for every 100,000 live births.
• There is a persistent pattern of presenting cutting-edge technology for the hydrocephalus market in industrialized nations like the United States and Canada before making it public elsewhere in the world. For example, CereVasc, a company working on the development of minimally invasive treatments for neurological disorders, announced the eShunt device in January 2021, which is used to treat hydrocephalus. This fuels the desire for cutting-edge methods of hydrocephalus treatment, which further supports the market's expansion.

Recent Developments

To take advantage of current business prospects, the businesses are concentrating on growing, diversifying their market presence, and obtaining a new consumer base. Companies are using both organic and inorganic techniques, such as acquisitions, to compete in the hydrocephalus industry. For instance:

• In June 2021, the SenSight Directional Lead System for Deep Brain Stimulation (DBS) therapy received FDA approval and underwent its first U.S. implantation, according to an announcement from Medtronic. It will increase their neurological product sales.
• In March 2021, a breakthrough device designation from the U.S. Food and Drug Administration (FDA) was given to Anuncia Inc for their ReFlow System Mini, which is meant to treat CSF problems. This permission has generated a continuous flow of income.
• In June 2020, Rhaeos, Inc.'s "FlowSense" noninvasive thermal sensor was granted FDA Breakthrough Device Designation.
• In May 2020, the M.blue valve was introduced by Aesculap, Inc. in collaboration with Christoph Miethke GmbH & Co. KG (MIETHKE). The M.blue valve combines a fixed differential pressure unit with cutting-edge gravitational technology in a single valve.
• In October 2017, Johnson & Johnson sold its Codman Neurosurgery Business to Integra LifeSciences Corporation for USD 1.045 billion.

Segments Analysis

By Type

“The congenital segment dominated the market share in 2021”.

The market is further segmented into congenital hydrocephalus, acquired hydrocephalus, normal-pressure hydrocephalus, and ex-vacuo hydrocephalus. In 2021, the congenital segment accounted for the biggest market share; throughout the forecast period, the segment is anticipated to see the highest CAGR.

By Diagnostic & Treatment Type

The market is divided into diagnostic and treatment.

By Age Group Type

“Pediatrics held the largest market share in 2021”.

The market is segmented into pediatric and adult. Pediatrics had a greater market share in 2021, and it is anticipated that it will grow at a faster rate throughout the projection period.

By End-User Type

“The hospital sector commanded the largest market share in 2021”.

The market is divided into hospitals, clinics, diagnostic centers, academic institutions, and research organizations. In 2021, the hospital sector had the biggest market share, and throughout the forecast period, it is anticipated to grow at the highest CAGR.

Regional Analysis

“North America was the leading market in 2021”.

The hydrocephalus market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America dominated the market for hydrocephalus shunts in 2021. 

Due to its stronger healthcare infrastructure, which encourages the use of technologically advanced shunts, and its rising hydrocephalus awareness, the US is a significant contributor to the market in this area. The National Institute of Neurological Disorders and Stroke (NINDS) estimates that 1-2 out of every 1,000 children born in the US will have hydrocephalus. According to the University of California's Los Angeles Health Organization, 125,000 Americans currently have cerebrospinal fluid shunts in place.

Key Players

The following are the key players in the Hydrocephalus Market (arranged alphabetically)

• Anuncia Inc.
• B. Braun Melsungen AG
• Bicakcilar
• CHRISTOPH MIETHKE GMBH & CO. KG
• Desu Medical
• G. SURGIWEAR LTD
• Integra LifeSciences
• KANEKA MEDIX CORP
• KARL STORZ SE & Co. KG
• Medtronic
• Möller Medical GmbH
• Natus Medical Incorporated
• Próteses, Inc.
• Sophysa
• Spiegelberg GmbH & Co.KG

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Write to us at sales@stratviewresearch.com

Report Features

This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.